AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00816192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term electrical isolation of pulmonary veins
Description: All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
Study NCT00816192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long-term electrical isolation of pulmonary veins
Description: All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
Study NCT03915470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XF-73
Description: XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
Study NCT03915470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match XF-73 nasal gel for colour and viscosity.
Study NCT03933761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
Study NCT03160898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet
Study NCT03160898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT02302872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTO System
Study NCT00862693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.5ug/Biw
Study NCT04090242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
Description: Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
Study NCT01969630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEB
Description: Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
Study NCT01969630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PES
Description: Systematic Paclitaxel eluting stent angioplasty
Study NCT00434109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
Study NCT00434109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Embolizations
Description: 1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
Study NCT01467921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
Study NCT01467921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
Study NCT00543777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastogram
Description: Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
Study NCT00543777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2-Point Dixon Magnetic Resonance Imaging
Description: Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
Study NCT03205176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5153
Description: AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
Study NCT03205176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib, 300 mg, will be taken BID as oral capsules.
Study NCT01205971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
Study NCT01205971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dental Preventive Services
Description: Written oral health educational materials
Study NCT01548066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
Study NCT01548066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo
Description: spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
Study NCT01773187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loperamide placebo
Description: 200 ml apple juice
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
Study NCT01596764 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Colon Transit
Description: 5 capsules containing radio-opaque markers of different shapes, respectively
Study NCT01596764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Transit
Description: 5 capsules containing radio-opaque markers of different shapes, respectively
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine
Description: Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MNTX and NLX
Description: Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
Study NCT01596764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone
Description: Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
Study NCT02340533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic endo-myometrial biopsy
Study NCT02340533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: two dimensional trans-vaginal ultrasonography
Study NCT01581632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LipiScan/LipiScan IVUS
Description: Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
Study NCT04680559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
Study NCT02896556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltrate
Description: A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
Study NCT01267188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
Study NCT01773187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Study NCT04160663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Carotid Ultrasound
Description: Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
Study NCT02956941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC on Essential Nutrition and Hygiene Actions (ENHAs)
Description: The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
Study NCT02777489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
Study NCT01180296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral micronized progesterone
Description: oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
Study NCT01180296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo tablet
Description: Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
Study NCT02925624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Study NCT00559221 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: FLAG+IDA
Description: Fludarabine, cytarabine, G-CSF
Study NCT05130749 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
Study NCT02921490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/MR examination.
Description: All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
Study NCT03948061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
Study NCT05138627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral cryotherapy
Description: Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
Study NCT02989883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: peroral endoscopic myotomy
Description: The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
Study NCT01618006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study NCT01618006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study NCT01618006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study NCT03141632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Evaluation visit with assessment of fluid intake
Study NCT03141632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Evaluation visit with assessment of fluid intake
Study NCT03858374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transferred by air-suspending mattress
Description: Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
Study NCT03858374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transferred by slide board
Description: When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
Study NCT03858374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transferred by bedsheet
Description: When patients need to be transferred from bed to bed, just lift the bedsheet.
Study NCT03323177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gender specific nutritional standardized formula
Description: Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
Study NCT03323177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up only
Description: Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
Study NCT01344083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1210
Description: 2 drops T1210 once a day
Study NCT01344083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride
Description: 2 drops once a day Olopatadine
Study NCT02956187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
Study NCT02956187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber supplement
Description: 3.5 g plantago ovata per day will be administered for 4 weeks.
Study NCT04247373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
Study NCT03839069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minor salivary gland transplantation
Description: The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
Study NCT02333058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan dose per day is to be calculated by using BSA:~One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2.
Study NCT01840345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-l-cysteine
Description: 1200 mg BID x 4 weeks
Study NCT02756117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Lysine
Study NCT02756117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal (0.9%) Saline
Study NCT04384055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
Study NCT06399237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot Orthoses
Description: Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO
Study NCT04190732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician phone call
Description: Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
Study NCT06449495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRVANA
Description: NIRVANA is a medical device using semi-immersive virtual reality for motor and cognitive neuro-rehabilitation.~NIRVANA creates a sensory room where the patient can have an immersive and stimulating experience by interacting directly with different realistic scenarios. The system creates different scenarios on the wall or floor, and the patient interacts with the stimuli provided. A motion-analysis device detects the patient's behavior and based on the projected environment provides highly stimulating and rehabilitative audiovisual feedback with full whole-body immersion. The system is preconfigured with a series of exercises, which can be customized based on different types of patients, intervening on the level of difficulty, speed of execution and sensitive area of the projection.
Study NCT01060696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic acid or Hyoscine or placebo
Description: Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
Study NCT03859908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML
Description: As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Study NCT02017470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gender-tailored women's heart health outpatient programme